The discovery: who invents and sells the world's medicines

A new medicine is, in business terms, a temporary monopoly. A company spends a decade and billions of dollars to discover a drug, win approval, and sell it — and for a fixed window, protected by patents, it can sell that drug with little direct competition. When the patents expire, cheap copies arrive and revenue can fall off a cliff. Almost everything about how pharmaceutical stocks behave — the enormous research budgets, the marketing, the constant deal-making — flows from the race against that clock.

Where this sits in the chain

The Discovery is the first link: where treatments are invented before anything else can happen. It feeds the entire chain downstream — the tools that test new drugs, the providers who prescribe them, the payers who fund them, and the middlemen who physically move them. For the bigger picture, start with the map in The System. Its riskier, earlier-stage cousin — biotech — is the next link, The Frontier.

What this link is

A large pharmaceutical company is really a portfolio of patents at different stages of life. A few terms make the rest of the series easier:

• Pipeline — the drugs a company has in development, from early lab work through to late-stage human trials. The pipeline is the future; today's sales are the past paying off.
• Blockbuster — an industry nickname for a drug earning more than $1 billion a year. A single blockbuster can define a company's fortunes.
• Patent cliff — the moment a key drug loses patent protection and faces cheap generic competition. Revenue can drop sharply and suddenly, which is why drugmakers must constantly replace their best sellers.

The whole game is replacing revenue faster than the cliffs erode it — through internal research or by buying smaller innovators outright (which is where this link connects to biotech).

The companies

Eli Lilly (LLY)

What they do: The company that turned obesity into pharma's biggest market. Lilly makes diabetes and weight-loss medicines (the GLP-1 class) alongside a broad drug portfolio. The numbers: [refresh: latest reported quarter revenue + YoY growth %; latest full-year revenue]. Growth in recent years has been driven overwhelmingly by demand for its obesity and diabetes franchise. The edge: an early, deep position in GLP-1 drugs and the manufacturing capacity to supply them at scale — a hard combination for rivals to match quickly. The risk: the company's value leans heavily on continued obesity-drug demand. Any setback — a supply stumble, a disappointing trial, pricing or reimbursement pressure, or faster-than-expected competition — would hit hard precisely because expectations are so high.

Johnson & Johnson (JNJ)

What they do: The diversified pharma-and-medtech bellwether — a sprawling business spanning prescription drugs and medical devices. (Its device arm reappears in The Devices.) The numbers: [refresh: latest quarter revenue, split between pharma and medtech]. The edge: breadth. Few rivals span both medicines and devices at this scale, which smooths the impact of any single product's decline. The risk: litigation — most prominently long-running talc-related lawsuits — plus patent exposure on key drugs. Legal liabilities are hard to size in advance.

Merck (MRK)

What they do: a research-driven drugmaker anchored by a leading cancer immunotherapy. The numbers: [refresh: latest quarter; share of revenue from its top oncology drug]. The edge: a dominant position in one of oncology's most important franchises, plus a vaccine and animal-health business. The risk: heavy revenue concentration in that one flagship drug, which faces its own patent cliff later this decade — the classic replacement problem in sharp form.

Pfizer (PFE)

What they do: a global drugmaker rebuilding after its pandemic-era revenue surge faded. The numbers: [refresh: latest quarter; note the post-COVID revenue decline]. The edge: scale and a large cash pile being redeployed into oncology through acquisitions. The risk: a steep drop from pandemic highs and pressure to prove its pipeline and deals can replace that lost revenue.

A note on who is missing. The other half of the weight-loss-drug story is Novo Nordisk, maker of Ozempic and Wegovy — but Novo is listed in Denmark, not the S&P 500, so this series treats it as context rather than profiling it. The same goes for AstraZeneca, Roche, Novartis, Sanofi, and GSK: global giants, but not US-index members.

The bull and bear case

The bull case: big pharma offers durable cash flows, real pricing power inside patent windows, and demand that grows as populations age. The obesity-drug wave has added a genuinely large new market on top.

The bear case: every drug is a melting asset. Patent cliffs are certain; the only question is whether the pipeline refills fast enough. On top of that sits US drug-pricing reform — Medicare can now negotiate prices on selected drugs — which chips at the monopoly economics the whole model relies on. Concentration in one or two blockbusters magnifies all of this.

Both can be true at once, and which dominates depends on the specific company and the specific year. We are describing the landscape, not telling you where to stand in it.

What feeds it, what it feeds

The Discovery is fed by the Frontier (where much new science originates, often acquired by big pharma) and the Tools (whose instruments make discovery possible). It feeds the Middlemen who distribute the drugs and the Payers who fund them. The forces that move every drugmaker at once — pricing politics, the obesity wave, patent cliffs — are gathered in The Forces. To step back to the whole map, return to The System.

This article is for information only and is not investment advice or a recommendation to buy or sell any security. [Publication] is not a licensed financial adviser. Figures are accurate as of June 2026 and will change. Markets carry risk, including loss of capital. Rules, taxes, and available products differ by country — do your own research and consider a locally regulated professional.